NGNE
Neurogene Inc.NASDAQHealthcare$20.69-4.48%ClosedMarket Cap: $322.2M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.20
P/S
0.00
EV/EBITDA
-2.50
DCF Value
$4.36
FCF Yield
-24.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-33.0%
ROA
-31.2%
ROIC
-37.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-24.7M | $-1.60 |
| FY 2025 | $0.00 | $-90.4M | $-4.24 |
| Q3 2025 | $0.00 | $-21.0M | $-0.99 |
| Q2 2025 | $0.00 | $-22.0M | $-1.05 |
Analyst Ratings
View AllHC Wainwright & Co.Buy
2026-01-13HC Wainwright & Co.Buy
2025-11-13HC Wainwright & Co.Buy
2025-10-09BMO CapitalOutperform
2025-06-12BairdNeutral
2025-05-16Trading Activity
Insider Trades
View AllJordan Julieofficer: Chief Medical Officer
SellMon Mar 30
McMinn Racheldirector, officer: Chief Executive Officer
SellMon Mar 30
Cvijic Christine Mikailofficer: President and CFO
SellMon Mar 30
Cvijic Christine Mikailofficer: President and CFO
SellTue Mar 17
Cvijic Christine Mikailofficer: President and CFO
SellTue Mar 17
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.89
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.